MedElevator
Войти в исследования International journal of dermatology · 2012
Cutaneous T cell lymphoma: update on treatment.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wollina Uwe
Аннотация
BACKGROUND: Cutaneous T-cell lymphoma (CTCL) is a myeloproliferative disease with pronounced epidermotropism. The major subtypes of CTCL are mycosis fungoides and Sézary syndrome. Survival is dependent on the histological subtype and clinical stage. Early CTCL has a normal life expectancy, therefore early disease recognition and stage adapted treatment might help to ensure a good prognosis.
METHODS: This is a review of recent advances in CTCL treatment based on literature review.
RESULTS: Skin targeted therapies are useful for patch and limited plaque disease with phototherapy as the cornerstone of such treatments. More advanced disease will benefit from systemic mono- or combined treatments including drug therapy, extracorporeal photopheresis, and radiotherapy. In practice combined treatments may reduce adverse events and improve response rates. For selected younger patients, stem cell transplantation seems a third-line option.
CONCLUSIONS: The therapeutic spectrum for CTCL has been advanced during the last years, providing the opportunity of tailored treatment for patients.
METHODS: This is a review of recent advances in CTCL treatment based on literature review.
RESULTS: Skin targeted therapies are useful for patch and limited plaque disease with phototherapy as the cornerstone of such treatments. More advanced disease will benefit from systemic mono- or combined treatments including drug therapy, extracorporeal photopheresis, and radiotherapy. In practice combined treatments may reduce adverse events and improve response rates. For selected younger patients, stem cell transplantation seems a third-line option.
CONCLUSIONS: The therapeutic spectrum for CTCL has been advanced during the last years, providing the opportunity of tailored treatment for patients.